Current Pharmacological Therapies in Heart Failure Patients: A Review, Lecture notes of Financial Accounting

Download Current Pharmacological Therapies in Heart Failure Patients: A Review and more Lecture notes Financial Accounting in PDF only on Docsity! HEART FAILURE PATIENTS REVIEW 1 NURS 615 Current Pharmacological Therapies In Heart Failure Patients Review Maryville University NURS 615: Advanced Pharmacotherapeutics For this assignment, I chose the article, Current pharmacological therapies in heart failure patients. The article by Muiesan et al. (2017) examines the health and social-economic implications of heart failure in the healthcare system and the current pharmacological interventions for treating the condition. Treatment guidelines of heart failure in the United States and Europe propose clinical differentiation between heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction(HFpEF). Pharmacological interventions guidelines for HFrEF are mostly uniform in the United States and Europe. The only difference occurs in the indication to second-line agents, namely ivabradine, hydralazine- isosorbide dinitrate in the treatment of HFrEF. For patients suffering from chronic heart failure, treatment guidelines require a dosage comprising a combination of angiotensin-converting enzyme (ACE)-I (or angiotensin receptor blocker (ARB) in cases where ACE is not tolerated), a beta-blocker and mineralocorticoid antagonist(MRA) (Muiesan et al., 2017). In patients suffering from heart failure with preserved ejection fraction(HFpEF), treatment guidelines require careful screening for cardiovascular and non-cardiovascular comorbidities. The screening helps improve health outcomes, promoting better control of symptoms and patient's well-being associated with non-cardiovascular conditions such as chronic obstructive pulmonary disease, diabetes, hypertension, and obesity in addition to prevention of